S. Hemrick-Luecke

发表

Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.

Gordon Campbell, J. Findlay, P. Gallagher, 2006, Bioorganic & medicinal chemistry letters.

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

K. Perry, F. Bymaster, S. Hemrick-Luecke, 2002, Neuropsychopharmacology.

Tropolone antagonism of the l−dopa‐induced elevation of S‐adenosylhomocysteine: S‐adenosylmethionine ratio but not depletion of adrenaline in rat hypothalamus

K. Perry, R. Fuller, S. Hemrick-Luecke, 1984, The Journal of pharmacy and pharmacology.

Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine

Todd R. Wiernicki, F. Bymaster, L. Nisenbaum, 2005, Journal of Pharmacology and Experimental Therapeutics.

The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.

D. Wong, T. Branchek, J. Zgombick, 2000, The Journal of pharmacology and experimental therapeutics.

Long-lasting depletion of striatal dopamine by a single injection of amphetamine in iprindole-treated rats.

R. Fuller, S. Hemrick-Luecke, 1980, Science.

Monoaminergic compensation in the neuropeptide Y deficient mouse brain

L. Thompson, S. Hemrick-Luecke, D. Gehlert, 2008, Neuropeptides.

Depletion of cardiac norepinephrine but not brain catecholamines by MPTP-N-oxide in mice.

R. Fuller, D. Robertson, S. Hemrick-Luecke, 1990, Life sciences.

Mechanisms of MPTP (1-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine) neurotoxicity to striatal dopamine neurons in mice

R. Fuller, S. Hemrick-Luecke, 1985, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Persistent depletion of striatal dopamine in mice by 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine (MTTP).

R. Fuller, D. Robertson, S. Hemrick-Luecke, 1986, Biochemical pharmacology.

Comparison of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP+) effects on mouse heart norepinephrine.

R. Fuller, D. Robertson, S. Hemrick-Luecke, 1988, Biochemical pharmacology.

Effect of 4-(4-methoxy-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydropyridine, an analog of MPTP, on mouse heart norepinephrine and brain catecholamines

R. Fuller, C. Mitch, S. Quimby, 1993, Neurochemistry International.

Tissue concentrations of MPTP and MPP+ in relation to catecholamine depletion after the oral or subcutaneous administration of MPTP to mice.

K. Perry, R. Fuller, S. Hemrick-Luecke, 1989, Life sciences.

Oral versus parenteral efficacy of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): differential effects on depletion of heart norepinephrine and of striatal dopamine in mice.

R. Fuller, S. Hemrick-Luecke, 1987, Biochemical pharmacology.

Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

K. Perry, R. Fuller, S. Hemrick-Luecke, 1988, The Journal of pharmacology and experimental therapeutics.

Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

R. Fuller, S. Hemrick-Luecke, 1985, Life sciences.

Effects of L-dopa on epinephrine concentration in rat brain: possible role of inhibition of norepinephrine N-methyltransferase by S-adenosylhomocysteine.

K. Perry, R. Fuller, S. Hemrick-Luecke, 1982, The Journal of pharmacology and experimental therapeutics.

A high dose of MPTP overcomes the protective effect of selegiline against dopaminergic neurotoxicity

R. Fuller, S. Hemrick-Luecke, SUSAN K. HEMRICK‐LUECKE, 1989, The Journal of pharmacy and pharmacology.

The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.

L. Thompson, S. Hemrick-Luecke, K. Rasmussen, 2006, Schizophrenia bulletin.

Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats

K. Perry, F. Bymaster, R. Fuller, 1996, Psychopharmacology.

Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)2 receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT2A receptor mediation of the HPA axis

S. Hemrick-Luecke, D. C. Evans, 2002, Neuropharmacology.

Further studies on the long-term depletion of striatal dopamine in iprindole-treated rats by amphetamine

R. Fuller, S. Hemrick-Luecke, 1982, Neuropharmacology.

The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding.

D. Wong, R. Fuller, S. Hemrick-Luecke, 1998, The Journal of pharmacology and experimental therapeutics.

(R)-thionisoxetine, a potent and selective inhibitor of central and peripheral norepinephrine uptake.

J. Howbert, D. Wong, R. Fuller, 1995, Life sciences.

Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain

J. Howbert, D. Wong, R. Fuller, 1995, Neurochemistry International.

Methylation of norepinephrine and α-methylnorepinephrine in brain

R. Fuller, S. Hemrick-Luecke, 1982 .

N-[2-(o-iodophenoxy)ethyl]cyclopropylamine hydrochloride (LY121768), a potent and selective irreversible inhibitor of type A monoamine oxidase.

R. Fuller, S. Hemrick-Luecke, B. Molloy, 1983, Biochemical pharmacology.

Lowering of dopamine metabolites in rat brain by harmaline

K. Perry, R. Fuller, S. Hemrick-Luecke, 1981, The Journal of pharmacy and pharmacology.

Influence of harmaline on the ability of pargyline to alter catecholamine metabolism in rats.

K. Perry, R. Fuller, S. Hemrick-Luecke, 1981, Biochemical pharmacology.

Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212.

R. Fuller, S. Hemrick-Luecke, 1996, European journal of pharmacology.

Muscarinic Agonist-Mediated Increases in Serum Corticosterone Levels Are Abolished in M2 Muscarinic Acetylcholine Receptor Knockout Mice

F. Bymaster, S. Hemrick-Luecke, C. Felder, 2002, Journal of Pharmacology and Experimental Therapeutics.

Efficacy of Duloxetine, a Potent and Balanced Serotonin-Norepinephrine Reuptake Inhibitor in Persistent Pain Models in Rats

S. Iyengar, S. Hemrick-Luecke, R. Simmons, 2004, Journal of Pharmacology and Experimental Therapeutics.

5'-THIODENOSINE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF HISTAMINE N-METHYL-TRANSFERASE

P. Crooks, R. Fuller, S. Hemrick-Luecke, 1989 .

Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist

R. Fuller, S. Hemrick-Luecke, C. M. Gust, 2005, Journal of Neural Transmission.

Species differences in epinephrine concentration and norepinephrine N-methyltransferase activity in hypothalamus and brain stem.

R. Fuller, S. Hemrick-Luecke, 1983, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

Substituted piperazines as central serotonin agonists: comparative specificity of the postsynaptic actions of quipazine and m-trifluoromethylphenylpiperazine.

J. Clemens, R. Fuller, S. Hemrick-Luecke, 1981, The Journal of pharmacology and experimental therapeutics.

Purkinje cell loss and the noradrenergic system in the cerebellum of pcd mutant mice

B. Ghetti, R. Fuller, S. Hemrick-Luecke, 1981, Brain Research Bulletin.

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

D. Wong, F. Bymaster, L. Thompson, 2001, Neuropsychopharmacology.

Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.

Kirk W. Johnson, G. Stephenson, J. Shah, 2013, ACS medicinal chemistry letters.

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

F. Bymaster, L. Thompson, S. Hemrick-Luecke, 2003, Neuropharmacology.

Pharmacological profile of LY301317, a potent and selective 5‐HT1A agonist

J. Gidda, R. Fuller, S. Hemrick-Luecke, 1997 .

Decreased hypothalamic epinephrine concentration by quipazine and other serotonin agonists in rats.

R. Fuller, S. Hemrick-Luecke, 1995, Biochemical pharmacology.

α2 andrenoreceptor affinity of some inhibitors of norepinephrine N-methyltransferase

R. Fuller, S. Hemrick-Luecke, R. E. Toomey, 1981 .

Fluoxetine at anorectic doses does not have properties of a dopamine uptake inhibitor

R. Fuller, S. Hemrick-Luecke, H. Snoddy, 2005, Journal of Neural Transmission / General Section JNT.

Altered behavioral response to a D2 agonist, LY141865, in spontaneously hypertensive rats exhibiting biochemical and endocrine responses similar to those in normotensive rats.

D. Wong, R. Fuller, S. Hemrick-Luecke, 1983, The Journal of pharmacology and experimental therapeutics.

Properties of 8,9-dichloro-2,3,4,5-tetrahydro-1H-2-benzazepine, an inhibitor of norepinephrine N-methyltransferase.

R. Fuller, S. Hemrick-Luecke, R. E. Toomey, 1981, Biochemical pharmacology.

Cardiovascular effects of LY134046, an inhibitor of norepinephrine N-methyltransferase, in spontaneously hypertensive rats.

R. Fuller, S. Hemrick-Luecke, R. A. Hahn, 1983, The Journal of pharmacology and experimental therapeutics.

Antagonism by L-dopa of the elevation of hypothalamic epinephrine by monoamine oxidase inhibition in rats.

R. Fuller, S. Hemrick-Luecke, 1981, Biochemical pharmacology.

Comparison of desmethylsertraline with sertraline as a monoamine uptake inhibitor in vivo

R. Fuller, S. Hemrick-Luecke, J. Audia, 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Serum Corticosterone Increases Reflect Enhanced Uptake Inhibitor‐induced Elevation of Extracellular 5−Hydroxytryptamine in Rat Hypothalamus

K. Perry, E. Engleman, R. Fuller, 1996, The Journal of pharmacy and pharmacology.

Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist

P. Ornstein, R. Fuller, S. Hemrick-Luecke, 1992, Neuropharmacology.

Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice.

R. Fuller, S. Hemrick-Luecke, H. Snoddy, 1994, The Journal of pharmacology and experimental therapeutics.

Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.

R. Fuller, D. Robertson, S. Hemrick-Luecke, 1987, The Journal of pharmacology and experimental therapeutics.

Comparison of 1-methyl-4-(p-chlorophenyl)-1,2,3,6-tetrahydropyridine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and p-chloroamphetamine as monoamine depletors.

R. Fuller, D. Robertson, S. Hemrick-Luecke, 1985, Research communications in chemical pathology and pharmacology.

Persistent depletion of striatal dopamine and cortical norepinephrine in mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydro-3-pyridinol (MPTP-3-OL), an analog of MPTP.

R. Fuller, J. Krushinski, D. Robertson, 1992, Life sciences.

MK801 antagonism of the prolonged depletion of striatal dopamine by amphetamine in iprindole-treated rats.

R. Fuller, S. Hemrick-Luecke, M. Henderson, 1992, Life sciences.

Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.

R. Fuller, S. Hemrick-Luecke, M. Kindt, 1988, Life Science.

Depletion of norepinephrine in mouse heart by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mimicked by 1-methyl-4-phenylpyridinium (MPP+) and not blocked by deprenyl.

R. Fuller, S. Hemrick-Luecke, 1986, Life sciences.

Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonists

K. Perry, R. Fuller, S. Hemrick-Luecke, 1985, The Journal of pharmacy and pharmacology.

Decrease in hypothalamic epinephrine concentration and other neurochemical changes produced by quinpirole, a dopamine agonist, in rats

R. Fuller, S. Hemrick-Luecke, Ray W. Fuller, 2005, Journal of Neural Transmission.

MK‐801 Protects Against Amphetamine‐Induced Striatal Dopamine Depletion in Iprindole‐Treated Rats, but not Against Brain Serotonin Depletion after p‐Chloroamphetamine Administration

R. Fuller, S. Hemrick-Luecke, M. Henderson, 1992, Annals of the New York Academy of Sciences.

Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

R. Fuller, S. Hemrick-Luecke, 1985, The Journal of pharmacology and experimental therapeutics.

Potent in vivo but not in vitro inhibition of monoamine oxidase by 3-chloro-α-phenylpyrazinemethanol

R. Fuller, S. Hemrick-Luecke, J. Ward, 1992, Neurochemistry International.

MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice.

R. Fuller, S. Hemrick-Luecke, C. J. Wong, 1986, Life sciences.

Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo.

S. Hemrick-Luecke, H. Snoddy, Ray W. Fuller, 1994, Life sciences.

Inhibition of brain epinephrine synthesis by 3,4-dichlorophenylethanolamine, a competitive substrate for norepinephrine N-methyltransferase.

K. Perry, R. Fuller, S. Hemrick-Luecke, 1983, Biochemical pharmacology.